Top

Published in:

21-12-2023 | Research

Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells

Authors: Mahtab Afsharzadeh, Jaleh Varshosaz, Mina Mirian, Farshid Hasanzadeh

Published in: Investigational New Drugs | Issue 1/2024

Summary

This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analysis on two cell lines of MCF-7 and NIH-3T3 were done including; cell viability test by MTT assay, cellular uptake, and cell cycle arrest by flow cytometry. The optimal liposomes showed the particle size of 123.6 ± 1.3 nm, drug loading efficiency and release efficiency of 83.87% ± 1.33% and 60.55% ± 0.46%, respectively. The RB loaded liposomes showed no hemolysis activity. Targeted liposomes increased cytotoxicity on MCF-7 cells more significantly than NIH-3T3 cells. Cell flow cytometry indicated that targeted liposomes uptake was superior to plain (non-targted) liposomes and free drug. Free drug and RB-loaded liposomes interrupted cell cycle in G1. However, amino acid-targeted liposomes arrested cells more than the free drug at this stage. Targeted liposomes reduced cell cycle with more interruption in the G2/M phase compared to the negative control.

Graphical abstract

Lima SM et al (2021) Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinMedicine 38:100985CrossRef

Al-Mahmood S et al (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8(5):1483–1507CrossRefPubMedPubMedCentral

Finn RS et al (2016) Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 18(1):17CrossRefPubMedPubMedCentral

Tosello G et al (2018) Breast surgery for metastatic breast cancer. Cochrane Database System Rev 3:CD011276

Slamon DJ et al (2020) Overall survival with Ribociclib plus fulvestrant in advanced breast cancer. New Eng J Med 382(6):514–524CrossRefPubMed

Shah A et al (2018) FDA approval: Ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin Cancer Res 24(13):2999–3004CrossRefPubMed

Arora S et al (2017) Project ECHO: an effective means of increasing palliative care capacity. Am J Manag Care 23(7):SP267–SP271

Liu D et al (2016) The smart drug delivery system and its clinical potential. Theranostics 6(9):1306–1323CrossRefPubMedPubMedCentral

Hurler J et al (2013) The effect of lipid composition and liposome size on the release properties of liposomes-in-hydrogel. Int J Pharm 456(1):49–57CrossRefPubMed

10.

Guimarães D et al (2021) Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm 601:120571CrossRefPubMed

11.

Yin Y et al (2022) Choline-induced SLC5A7 impairs colorectal cancer growth by stabilizing p53 protein. Cancer Let 525:55–66CrossRef

12.

Gynther M et al (2010) Brain uptake of ketoprofen-lysine prodrug in rats. Int J Pharm 399(1–2):121–128CrossRefPubMed

13.

Wu W et al (2015) Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors. Cancer Sci 106(6):747–756CrossRefPubMedPubMedCentral

14.

Shennan DB et al (2004) L-Leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): Kinetics, regulation by estrogen and molecular identity of the transporter. Biochim et Biophy Acta - Biomembranes 1664(2):206–216CrossRef

15.

Metselaar JM et al (2003) A novel family of l-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14(6):1156–1164CrossRefPubMed

16.

Li L et al (2016) Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloid Surf B: Biointerf 141:260–267CrossRef

17.

Li L et al (2017) Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy. Nanomed Nanotech Biol Med 13(3):987–998ADSCrossRef

18.

Wang Z et al (2019) Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB0,+ for efficient tumor therapy. J Control Rel 316:22–33CrossRef

19.

Brandl M (2001) Liposomes as drug carriers: A technological approach. Biotechnol Annu Rev 7:59–85CrossRefPubMed

20.

Pinto F et al (2018) Design of multifunctional nanostructured lipid carriers enriched with α-tocopherol using vegetable oils. Ind Crops Product 118:149–159CrossRef

21.

Kępczyński M et al (2008) Which physical and structural factors of liposome carriers control their drug-entrapment efficiency. Chem Phys Lipid 155(1):7–15

22.

Zhao L et al (2015) Preparation of liposomes using supercritical carbon dioxide technology: Effects of phospholipids and sterols. Food Res Int 77:63–72CrossRef

23.

Hua S, Wu SY (2013) The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol 4:143CrossRefPubMedPubMedCentral

24.

Accardo A, Morelli G (2015) Peptide-targeted liposomes for selective drug delivery: advantages and problematic issues. Biopolymers 104(5):462–479CrossRefPubMed

25.

Hong SS et al (2015) Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. Int J Pharm 483(1–2):142–150CrossRefPubMed

26.

Kaddah S et al (2018) Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem Toxicol 113:40–48CrossRefPubMed

27.

Luo Q et al (2016) Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB°+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. J Control Rel 243:370–380CrossRef

28.

Kim CK, Park DK (1987) Stability and drug release properties of liposomes containing cytarabine as a drug carrier. Arch Pharm Res 10(2):75–79CrossRef

29.

Papageorgiou F et al (2019) Physicochemical study of the protein–liposome interactions: influence of liposome composition and concentration on protein binding. J Liposome Res 29(4):313–321CrossRef

30.

Arnida et al (2011) Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm 77(3):417–423CrossRefPubMed

31.

Sartaj A et al (2022) Ribociclib nanostructured lipid carrier aimed for breast cancer: formulation optimization, attenuating in vitro specification, and in vivo scrutinization. BioMed Res Int 2022:6009309CrossRefPubMedPubMedCentral

32.

Nakanishi T et al (2011) Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J Pharm Sci 100(9):3731–3750CrossRefPubMed

33.

Salatin S et al (2015) Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int 39(8):881–890CrossRefPubMed

34.

Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20(13):3379–3383CrossRefPubMed

35.

Kommineni N et al (2022) Stealth liposomal chemotherapeutic agent for triple negative breast cancer with improved pharmacokinetics. Nanotheranostics 6(4):424–435CrossRefPubMedPubMedCentral

36.

Al-Shdefat R et al (2023) Ribociclib hybrid lipid–polymer nanoparticle preparation and characterization for cancer treatment. Polymers 15(13):2844CrossRefPubMedPubMedCentral

Title: Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
Authors: Mahtab Afsharzadeh
Jaleh Varshosaz
Mina Mirian
Farshid Hasanzadeh
Publication date: 21-12-2023
Publisher: Springer US
Published in: Investigational New Drugs / Issue 1/2024
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-023-01409-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide

Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer